Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 24Carcinoma, Transitional Cell 6Urinary Bladder Neoplasms 3Carcinoma, Renal Cell 3Small Cell Lung Carcinoma 2Sarcoma 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Lung Neoplasms 2Disease 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2mCRPC (Metastatic Castration-resistant Prostate Cancer) 1Uterine Cervical Neoplasms 1Tuberous Sclerosis 1Thyroid Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Rectal Neoplasms 1Prostate Cancer Metastatic 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1

Interventions

Blood Specimen Collection 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3Surveys and Questionnaires 2Prednisone 2Positron-Emission Tomography 2Magnetic Resonance Imaging 2Injections 2vistusertib 1technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1pembrolizumab 1lortalamine 1ioflupane 1gossypol acetic acid 1carbon-11 acetate 1abiraterone 1Waiting Lists 1Urine Specimen Collection 1Urination 1Transcutaneous Electric Nerve Stimulation 1Therapeutics 1Specimen Handling 1Referral and Consultation 1Prostatectomy 1Preoperative Exercise 1Positron Emission Tomography Computed Tomography 1Pluvicto 1Observation 1Music Therapy 1Multiparametric Magnetic Resonance Imaging 1Mitomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Disease × Injections × Genitourinary × Clear all
NCT04186845 2025-09-22

Spotlight

Blue Earth Diagnostics

Phase 3 Completed
391 enrolled 30 charts
Genitourinary

Disease, Prostatic Neoplasms

NCT04186819 2025-02-26

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.

Blue Earth Diagnostics

Phase 3 Completed
356 enrolled 28 charts
Genitourinary

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡